The FDA's updated stance on Zika, by Dr Nicola Davies
On August 26, 2016, the US Food and Drug Administration (FDA) issued revised guidance recommending universal testing of donated Whole Blood and blood components for Zika virus in the USA and all of its territories.
These revised guidelines recommend that all blood collection establishments screen individual units of donated Whole Blood and blood components using a blood screening test, while an FDA-approved pathogen reducing device is to be used for plasma and platelet products, explains Dr Nicola Davies in her exclusive monthly FDA blog for The Pharma Letter.
Additional precautionary measures are necessary as new scientific and epidemiological information is slowly becoming available. Expanded testing will ensure that the risk for transmission of the Zika virus through the blood supply is reduced.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze